Eurocine Vaccines AB (publ) reported earnings results for the second quarter and six months ended December 31, 2023. For the second quarter, the company reported revenue was SEK 0.005 million compared to SEK 0.001 million a year ago. Net loss was SEK 6.74 million compared to SEK 6.18 million a year ago. Basic loss per share from continuing operations was SEK 0.07. Diluted loss per share from continuing operations was SEK 0.07.
For the six months, revenue was SEK 0.005 million compared to SEK 0.003 million a year ago. Net loss was SEK 8.76 million compared to SEK 12.06 million a year ago.